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The expression of IL-21 is promoted by MEKK4 in malignant T cells and 40 associated with increased progression risk in cutaneous T-cell lymphoma 41 42
Signaling through Interleukin-2 (IL-2) receptor gamma (IL-2Rg) via the cytokines IL-43 2, IL-4, IL-7, IL-15, and IL-21 has been implicated in the pathogenesis of cutaneous 44 T-cell lymphomas (CTCL) (Marzec et al., 2008) . Extensive research has documented 45 that IL-2, IL-7, and IL-15 stimulate proliferation of malignant T cells, while IL-4 is 46 known to promote a Th2 type inflammatory response within the affected skin. In 47 contrast, the role of IL-21 remains unclear since IL-21 was shown to exert both pro-48 and anti-tumorigenic responses. On the one hand, IL-21 stimulates anti-tumor 49
cytotoxic T cells and NK cells, which leads to inhibition of tumor growth in vivo in a 50
number of cancer models (Sondergaard et al., 2007; Spolski and Leonard, 2014) , 51 while on the other hand, it activates the proto-oncogene Signal Transducer and 52
Activator of Transcription (STAT3) (Marzec et al., 2008) , which ultimately promotes 53 expression of pro-inflammatory cytokines and survival factors in malignant T cells 54 (Sommer et al., 2004) . 55 56 Interestingly, IL-21 itself is also a target of STAT3 suggesting the existence of a 57 vicious circle, where IL-21 stimulates STAT3 activation, which in turn up-regulates 58 IL-21 expression (van der Fits et al., 2012) . However, IL-21 expression was only 59 partly reduced following inhibition of STAT3 signaling (van der Fits et al., 2012) and 60 IL-21 blockade did not block STAT3 activation (van der Fits et al., 2014) indicating 61 that other pathways are also involved in IL-21 expression in malignant T cells. 62
The Mitogen-Activated Protein (MAP) KinaseKinaseKinase (MEKK4/ MAP3K4) 63 was recently shown to drive IL-21 expression in CD4 + T cells from patients with 64
Systemic Lupus Erythematosus (SLE) (Lee et al., 2014) , but this has not been 65 documented in CTCL. Yet, a downstream MAP Kinase, p38, is constitutive active in 66 this malignancy and associated with disease progression (Bliss-Moreau et al., 2015) . 67
68
To elucidate this signaling pathway we addressed whether MEKK4 and p38 were 69 involved in the regulation of IL-21 mRNA expression in patient-derived malignant T 70 cells lines. As shown in Fig. 1A , siRNA-mediated inhibition of MEKK4 resulted in a 71 significant inhibition of MEKK4 (Fig. 1A, left) and IL-21 mRNA expression (Fig.  72 1A, right) providing the evidence that MEKK4 promotes IL-21 expression in 73 malignant T cells. As expected, siRNA-mediated knock down of STAT3 inhibited IL-74 21 expression whereas STAT5 knock down had no effect (Fig. 1B) . This observation 75 is consistent with previous findings that IL-21 is a STAT3 target gene in malignant T 76 cells. Importantly, STAT3 siRNA had no inhibitory effect on the expression of 77 MEKK4 indicating that MEKK4 is not a down-stream effector of STAT3 (Fig. 1B) . 78
79
Our findings further revealed that MEKK4 regulates STAT3 phosphorylation. 80
Specifically, siRNA-mediated knock down of MEKK4 resulted in a decrease in serine 81 phosphorylation of STAT3 as judged by Western Blot analysis using a phosphoserine 82 (P-ser727) specific antibody (Fig. 1C, left) , whereas the total amount of STAT3 83 protein was not decreased (Fig. 1C, right) . As expected, IL-21 mRNA expression was 84 also inhibited by this treatment (Fig. 1C, right) . Importantly, a dual knock down of 85 STAT3 and MEKK4 significantly inhibited IL-21 expression, but to no greater extend 86 than the inhibition of STAT3 or MEKK4 alone (Fig. 1C) implying that both 87 treatments target the same pathway and that ser727 phosphorylation is required for 88 STAT3-mediated IL-21 transcription. Thus, these findings provide evidence for aM A N U S C R I P T
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5 link between MEKK4 signaling and STAT3-S727 serine phosphorylation and suggest 90 that MEKK4 augments IL-21 expression via this mechanism. Notably, increased 91 STAT3 serine phosphorylation at residue S727 was previously shown to enhance 92 transcriptional activity of STAT3 (Zhang et al., 1995) . 93
94
The p38 MAP Kinase induces serine-727 phosphorylation of STAT3 and is a well-95 established down-stream effector of MEKK4 (Platanias, 2003) . Hence, we next 96 addressed the role of p38 in the regulation of IL-21 expression in malignant T cells. 97
To achieve this, we utilized an inhibitor of p38 (SB203580), which blocks IL-2 98 induced serine phosphorylation of STAT3 (Gollob et al., 1999) . As shown in Fig. 1D , 99
SB203580 induced a dose-dependent inhibition of IL-21 expression indicating that 100
p38 indeed promoted the expression of IL-21. Essentially similar results were 101 obtained in two independent experiments using primary malignant T cells (>90% pure 102 as judged from TCR-Vb staining) isolated from peripheral blood from a Sezary 103
Syndrome patient (Fig 1D right) . Recently, Aurora kinases A and B were shown to be 104 highly overexpressed and activated in CTCL skin lesions (Humme et al., 2015) . As 105 p38 is a down-stream effector of Aurora kinases in other cancers, it is tempting to 106 speculate that Aurora kinases are involved in IL-21 expression by malignant T cells. IL-21 expression between CTCL lesional skin, normal skin samples derived from 117 healthy volunteers (N=6), and benign inflammatory dermatoses that often mimic this 118 malignancy (e.g., psoriasis, pityriasis rubra pilaris and chronic eczema) (N=12) 119 (Litvinov et al., 2010) . All patients were enrolled in the IRB-approved study protocol 120 with written, informed consent in accordance with the Declaration of Helsinki 121 (Litvinov et al., 2015) . 122
123
As presented, in Table S1 , IL-21 was expressed in early and advanced stages of 124 CTCL, therefore, suggesting that IL-21 is not simply a surrogate marker for advanced 125 disease. IL-21 was also increased in skin samples from CTCL patients compared to 126 benign inflammatory dermatoses and healthy controls ( M1  M2  M5A  M5E  M7  M8  M9  M10  M11  M12  M13  M14  M15  M16  M17  M18  M19  M20  M21  M22  M23  M24  M25  M27  M28  M29  M30  M31  M33  M34  M35  M36  M37  M38  M40  M41  M42  M43  M44  M45  M46  M47  M48  M49  M50  M51  M52  M53  M54  M54.2  M55  M56  M57  M58  M59  M60  M61  M62  M63  M64 
